CMX 521

Drug Profile

CMX 521

Alternative Names: CMX-521

Latest Information Update: 08 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chimerix
  • Class Antivirals; Drug conjugates; Small molecules
  • Mechanism of Action DNA-directed RNA polymerase modulators; Nucleoside reverse transcriptase inhibitors; Polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Norovirus infections

Most Recent Events

  • 23 Jan 2018 Chimerix plans to initiate challenge/proof-of-concept clinical trial in 2019
  • 23 Jan 2018 Chimerix plans to initiate phase I multiple dose study in 2H 2018
  • 10 Jan 2018 Chimerix plans for patent protection for CMX 521 in 2036
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top